Trials / Unknown
UnknownNCT03903393
Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 260 (estimated)
- Sponsor
- First Affiliated Hospital of Harbin Medical University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To identify lncRNAs differentially expressed at early stages of gestation in the serum of pregnant women, who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with normal pregnancy .
Detailed description
Preeclampsia (PE) is a pregnancy syndrome characterized by hypertension and proteinuria, and a leading cause of maternal and fetal morbidity and mortality, with poorly defined pathophysiological mechanisms remain. Circulating lncRNAs are long, noncoding RNA molecules, which negatively regulate gene expression, and considered as promising biomarkers for PE. The objective of the study is to evaluate circulating lncRNA signatures in women with PE compared to healthy women, and in women sub-grouped per PE severity. This study assessed lncRNA expression profile in the serum at early stages of gestation of women who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with uncomplicated pregnancies. Circulating lncRNA was extracted from maternal serum. This study also assess lncRNA expression profile in the placenta tissues of PE patients and healthy pregnant women.
Conditions
Timeline
- Start date
- 2019-03-31
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
- First posted
- 2019-04-04
- Last updated
- 2019-12-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03903393. Inclusion in this directory is not an endorsement.